Cantex Pharmaceuticals

Focus: Cantex Pharmaceuticals is an oncology-focused pharmaceutical company based in Weston, FL, developing novel cancer therapies including repurposed drugs and investigational compounds.

Oncology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Cantex Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Cantex Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Change in SARS-CoV-2 Antibody Levels

Covid-19

N/A

Disulfiram

Multiple Myeloma

Phase 1

Clinical Trials (1)

Help build intelligence for Cantex Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to early-stage oncology programs across multiple modalities (small molecules, copper-based therapies) with potential for rapid advancement
Focused pipeline in high-unmet-need cancer indications including glioblastoma and pancreatic cancer
Opportunity to contribute to pre-commercial development phases with direct scientific impact

Watch Out For

Zero active job openings suggest company is not actively expanding workforce or may be in early stealth/capital-raising phase
No marketed products or revenue generation—all financial stability metrics unavailable (funding, cash position, revenue data unknown)
Early-stage pipeline with no Phase 3 programs indicates 5+ years to potential first approval; no near-term clinical catalysts or value inflection points visible

Generated by Claude from Cantex Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.